Literature DB >> 24346752

Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.

Sebastian Walther1, Franz Moggi, Helge Horn, Konstantin Moskvitin, Christoph Abderhalden, Nadja Maier, Werner Strik, Thomas J Müller.   

Abstract

INTRODUCTION: Agitation is a major problem in acute schizophrenia. Only a few studies have tested antipsychotic agents in severely agitated patients, mainly because of legal issues. Furthermore, most studies were limited to the first 24 hours. We aimed to investigate the efficacy of oral haloperidol, risperidone, and olanzapine in reducing psychotic agitation in severely agitated patients with schizophrenia or schizophreniform or schizoaffective disorder over 96 hours using a prospective, randomized, rater-blinded, controlled design within a naturalistic treatment regimen.
METHODS: In total, 43 severely agitated patients at acute care psychiatric units were enrolled. Participants were randomly assigned to receive either daily haloperidol 15 mg, olanzapine 20 mg, or risperidone 2 to 6 mg over 5 days. Positive and Negative Syndrome Scale psychotic agitation subscale score was the primary outcome variable. A mixed-model analysis was applied.
RESULTS: All drugs were effective for rapid tranquilization within 2 hours. Over 5 days, the course differed between agents (P < 0.001), but none was superior. Dropouts occurred only in the risperidone and olanzapine groups. Men responded better to treatment than did women during the initial 2 hours (P = 0.046) as well as over the 5-day course (P < 0.001). No difference between drug groups was observed regarding diazepam or biperiden use.
CONCLUSIONS: Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders. Response to oral antipsychotics demonstrated a gender effect with poorer outcome in women throughout the study.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24346752     DOI: 10.1097/JCP.0000000000000050

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  13 in total

Review 1.  Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).

Authors:  Edoardo G Ostinelli; Melanie J Brooke-Powney; Xue Li; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2017-07-31

2.  Gender-specific research on mental illness in the emergency department: current knowledge and future directions.

Authors:  Megan L Ranney; Natalie Locci; Erica J Adams; Marian Betz; David B Burmeister; Ted Corbin; Preeti Dalawari; Jeanne L Jacoby; Judith Linden; Jonathan Purtle; Carol North; Debra E Houry
Journal:  Acad Emerg Med       Date:  2014-11-20       Impact factor: 3.451

Review 3.  The Use of Rapid Tranquilization in Aggressive Behavior.

Authors:  Sophie Hirsch; Tilman Steinert
Journal:  Dtsch Arztebl Int       Date:  2019-06-28       Impact factor: 5.594

4.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

5.  Comparison of haloperidol and midazolam in restless management of patients referred to the Emergency Department: A double-blinded, randomized clinical trial.

Authors:  Mehrdad Esmailian; Omid Ahmadi; Mehrsa Taheri; Majid Zamani
Journal:  J Res Med Sci       Date:  2015-09       Impact factor: 1.852

Review 6.  Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review.

Authors:  Xin Yu; Christoph U Correll; Yu-Tao Xiang; Yifeng Xu; Jizhong Huang; Fude Yang; Gang Wang; Tianmei Si; John M Kane; Prakash Masand
Journal:  Shanghai Arch Psychiatry       Date:  2016-10-25

7.  Prescription practices in the treatment of agitation in newly hospitalized Chinese schizophrenia patients: data from a non-interventional naturalistic study.

Authors:  Su-Zhen Zhang; Yong-Gang Mu; Qi Liu; Ying Shi; Li-Hua Guo; Ling-Zhi Li; Fu-De Yang; Yong Wang; Tao Li; Qi-Yi Mei; Hong-Bo He; Zhi-Yu Chen; Zhong-Hua Su; Tie-Bang Liu; Shi-Ping Xie; Qing-Rong Tan; Jin-Bei Zhang; Cong-Pei Zhang; Hong Sang; Wei-Feng Mi; Hong-Yan Zhang
Journal:  BMC Psychiatry       Date:  2019-07-10       Impact factor: 3.630

Review 8.  Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).

Authors:  Edoardo G Ostinelli; Mohsin Hussein; Uzair Ahmed; Faiz-Ur Rehman; Krista Miramontes; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2018-04-10

9.  Safety and effectiveness of rapid-acting intra-muscular olanzapine for agitation associated with schizophrenia - Japan postmarketing surveillance study.

Authors:  Hideaki Katagiri; Masanori Taketsuna; Shinpei Kondo; Kenta Kajimoto; Etsuko Aoi; Yuka Tanji
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-12       Impact factor: 2.570

Review 10.  Treatment Options for Acute Agitation in Psychiatric Patients: Theoretical and Empirical Evidence.

Authors:  Nicholas Zareifopoulos; George Panayiotakopoulos
Journal:  Cureus       Date:  2019-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.